

CorMedix Inc.
Form 8-K
January 13, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 13, 2014

CORMEDIX INC.
(Exact Name of
Registrant as
Specified in
Charter)

Delaware	001-34673	20-5894890
(State or Other		
Jurisdiction		(IRS Employer
of	(Commission	Identification
Incorporation)	File Number)	No.)

745 Rt. 202-206,
Suite 303,
Bridgewater, NJ 08807
(Address of
Principal
Executive (Zip
Offices) Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed
Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: CorMedix Inc. - Form 8-K

- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01. Other Events.

On January 13, 2014, CorMedix issued a press release announcing the establishment of letters of intent for the importation, sales, marketing and distribution of the Neutrolin® catheter lock solution with two leading Middle East distributors, as well as the establishment of a Sales and Marketing Oversight Committee of our Board of Directors.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
----------------	-------------

<u>99.1</u>	Press release dated January 13, 2014.
-------------	---------------------------------------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: January 13, 2014

By: /s/ Randy Milby
Name: Randy Milby
Title: Chief Executive Officer